# Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X)

> **NCT02938962** · PHASE4 · UNKNOWN · sponsor: **Mount Sinai Hospital, Canada** · enrollment: 160 (estimated)

## Conditions studied

- Tranexamic Acid
- Blood Loss, Surgical
- Arthroplasty, Replacement, Hip

## Interventions

- **DRUG:** Tranexamic Acid

## Key facts

- **NCT ID:** NCT02938962
- **Lead sponsor:** Mount Sinai Hospital, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-11
- **Final completion:** —
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2016-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02938962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02938962, "Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02938962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*